12.12.2012 Views

ISBN: 978-83-60043-10-3 - eurobic9

ISBN: 978-83-60043-10-3 - eurobic9

ISBN: 978-83-60043-10-3 - eurobic9

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Eurobic9, 2-6 September, 2008, Wrocław, Poland<br />

P<strong>10</strong>3. Square-Planar Metallointercalators as Potential Anticancer Agents<br />

A. Krause-Heuer a , N. Orkey a , B. Singh a , J. Aldrich-Wright a<br />

a School of Biomedical and Health Sciences, University of Western Sydney, Narellen Road, 2560, Campbelltown,<br />

Australia<br />

e-mail: j.Aldrich-Wright@uws.edu.au<br />

The majority of clinically used platinum-based anticancer agents (eg cisplatin and carboplatin) effect their<br />

cytotoxic action by coordinating to specific atoms in the base-pairs of the DNA helix. However, unfavourable<br />

side effects such as nephrotoxicity and neurotoxicity are associated with these drugs. In an attempt to overcome<br />

the potential side effects with such drugs, a series of platinum(II) compounds have been innovatively designed<br />

which interact via a completely different mechanism – intercalation. These square-planar metallointercalators are<br />

composed of two bidentate ligands positioned around the platinum(II) metal centre: an intercalating moiety and a<br />

non-intercalating (ancillary) group. The planar intercalating segment is comprised of a minimum of three<br />

aromatic rings fused together and both chiral and achiral ancillary ligands have been utilised. The first compound<br />

in our series of platinum(II) metallointercalators was 1S, 2S diaminocyclohexane-1, <strong>10</strong>-phenanthroline<br />

platinum(II). This compound displays a higher level of activity than cisplatin in all cell lines tested and is up to<br />

twenty times more soluble in water. These features suggest that this and similar compounds may demonstrate<br />

higher clinical effectiveness and lower toxicity than platinum-based compounds in clinical use. In vitro<br />

experiments have shown these complexes to be biologically active. The binding affinities of these compounds<br />

have also been investigated through UV-vis and CD spectroscopy.<br />

References:<br />

[1] Fenton, R. R.; Aldrich-Wright, J. R. In PCT Int. Appl.: Australia, 2002, pp 1-26.<br />

_____________________________________________________________________<br />

222

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!